Literature DB >> 18223170

CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.

Catherine Matte-Martone1, Jinli Liu, Dhanpat Jain, Jennifer McNiff, Warren D Shlomchik.   

Abstract

Whether T-cell antigen receptors (TCR) on donor T cells require direct interactions with major histocompatibility complex class I or class II (MHCI/MHCII) molecules on target cells to mediate graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) is a fundamental question in allogeneic stem-cell transplantation (alloSCT). In MHC-mismatched mouse models, these contacts were not required for GVHD. However, this conclusion may not apply to MHC-matched, multiple minor histocompatibility antigen-mismatched alloSCT, the most common type performed clinically. To address this, we used wild-type (wt)-->MHCI-/- or wt-->MHCII-/- bone marrow chimeras as recipients in GVHD experiments. For GVL experiments, we used MHCI-/- or MHCII-/- chronic-phase CML cells created by expressing the BCR-ABL cDNA in bone marrow from MHCI-/- or MHCII-/- mice. TCR/MHCI contact was obligatory for both CD8-mediated GVHD and GVL. In contrast, CD4 cells induced GVHD in wt-->MHCII-/- chimeras, whereas MHCII-/- mCP-CML was GVL-resistant. Donor CD4 cells infiltrated affected skin and bowel in wt-->MHCII-/- recipients, indicating that they mediated GVHD by acting locally. Thus, CD4 cells use distinct effector mechanisms in GVHD and GVL: direct cytolytic action is required for GVL but not for GVHD. If these noncytolytic pathways can be inhibited, then GVHD might be ameliorated while preserving GVL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223170      PMCID: PMC2275040          DOI: 10.1182/blood-2007-11-125294

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Role of endogenous peptides in murine allogenic cytotoxic T cell responses assessed using transfectants of the antigen-processing mutant 174xCEM.T2.

Authors:  D B Crumpacker; J Alexander; P Cresswell; V H Engelhard
Journal:  J Immunol       Date:  1992-05-15       Impact factor: 5.422

Review 2.  Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy.

Authors:  C L Mackall; R E Gress
Journal:  Immunol Rev       Date:  1997-06       Impact factor: 12.988

Review 3.  Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm.

Authors:  T A Springer
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

4.  Production of high-titer helper-free retroviruses by transient transfection.

Authors:  W S Pear; G P Nolan; M L Scott; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

Review 5.  Restoration of T-cell homeostasis after T-cell depletion.

Authors:  C L Mackall; F T Hakim; R E Gress
Journal:  Semin Immunol       Date:  1997-12       Impact factor: 11.130

6.  Induction of MHC class II gene products in rat intestinal epithelium during graft-versus-host disease and effects on the immune function of the epithelium.

Authors:  P W Bland; C V Whiting
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

7.  Transient expression of full-length and truncated forms of the human nerve growth factor receptor.

Authors:  U R Reddy; G Venkatakrishnan; G G Maul; A K Roy; A H Ross
Journal:  Brain Res Mol Brain Res       Date:  1990-07

8.  Role of endogenous peptide in human alloreactive cytotoxic T cell responses.

Authors:  S Man; R D Salter; V H Engelhard
Journal:  Int Immunol       Date:  1992-03       Impact factor: 4.823

9.  Lymphocyte recruitment in delayed-type hypersensitivity. The role of IFN-gamma.

Authors:  T B Issekutz; J M Stoltz; P vd Meide
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

10.  Major histocompatibility complex class II expression by intrinsic renal cells is required for crescentic glomerulonephritis.

Authors:  S Li; C Kurts; F Köntgen; S R Holdsworth; P G Tipping
Journal:  J Exp Med       Date:  1998-08-03       Impact factor: 14.307

View more
  21 in total

1.  Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.

Authors:  Yi-Fen Lu; L Cristina Gavrilescu; Monica Betancur; Katherine Lazarides; Hans Klingemann; Richard A Van Etten
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

2.  Recipient B cells are not required for graft-versus-host disease induction.

Authors:  Catherine Matte-Martone; Xiajian Wang; Britt Anderson; Dhanpat Jain; Anthony J Demetris; Jennifer McNiff; Mark J Shlomchik; Warren D Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-23       Impact factor: 5.742

Review 3.  Biology of graft-versus-host responses: recent insights.

Authors:  Kelli P MacDonald; Warren D Shlomchik; Pavan Reddy
Journal:  Biol Blood Marrow Transplant       Date:  2013-01       Impact factor: 5.742

4.  In vivo dynamics of T cells and their interactions with dendritic cells in mouse cutaneous graft-versus-host disease.

Authors:  Sarah Morin-Zorman; Christian Wysocki; Jieqing Zhu; Hongmei Li; Sylvain Zorman; Catherine Matte-Martone; Edwina Kisanga; Jennifer McNiff; Dhanpat Jain; David Gonzalez; David M Rothstein; Fadi G Lakkis; Ann Haberman; Warren D Shlomchik
Journal:  Blood Adv       Date:  2019-07-23

Review 5.  Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  N Engl J Med       Date:  2017-11-30       Impact factor: 91.245

6.  A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease.

Authors:  Isao Tawara; Warren D Shlomchik; Angela Jones; Weiping Zou; Evelyn Nieves; Chen Liu; Tomomi Toubai; Raimon Duran-Struuck; Yaping Sun; Shawn G Clouthier; Rebecca Evers; Kathleen P Lowler; Robert B Levy; Pavan Reddy
Journal:  J Immunol       Date:  2010-09-01       Impact factor: 5.422

7.  Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant.

Authors:  Catherine Matte-Martone; Srividhya Venkatesan; Hung Sheng Tan; Ioanna Athanasiadis; Julia Chang; Jovana Pavisic; Warren D Shlomchik
Journal:  J Immunol       Date:  2011-07-18       Impact factor: 5.422

8.  Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution.

Authors:  Ning Li; Catherine Matte-Martone; Hong Zheng; Weiguo Cui; Srividhya Venkatesan; Hung Sheng Tan; Jennifer McNiff; Anthony J Demetris; Derry Roopenian; Susan Kaech; Warren D Shlomchik
Journal:  Blood       Date:  2011-09-13       Impact factor: 22.113

9.  PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.

Authors:  Kathryn W Juchem; Faruk Sacirbegovic; Cuiling Zhang; Arlene H Sharpe; Kerry Russell; Jennifer M McNiff; Anthony J Demetris; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

10.  Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation.

Authors:  Kai Sun; Minghui Li; Thomas J Sayers; Lisbeth A Welniak; William J Murphy
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.